In8Bio INAB
NASDAQ INAB
$1.40 +0.07 (+5.26%)
At close: Oct 1, 2026 · 4:00 PM EDT

In8Bio (INAB) Preferred Stock Liabilities (2020 - 2021)

Updated

In8Bio's Preferred Stock Liabilities came in at $34.9 million for Q2 2021, up 143.1% from $14.36 million a year earlier and unchanged from the prior quarter.

Analysis

In8Bio (INAB) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends

Going back to Q2 2020, In8Bio's Preferred Stock Liabilities data covers 5 quarters.

  • Business Quant data shows INAB's Preferred Stock Liabilities at $34.9 million (Q1 2021), $34.9 million (Q4 2020) and $34.07 million (Q3 2020) in the three quarters before Q2 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 In8Bio 25.89 Mn 25.89 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2021 34.90 Mn
Mar 31, 2021 34.90 Mn
Dec 31, 2020 34.90 Mn
Sep 30, 2020 34.07 Mn
Jun 30, 2020 14.36 Mn
API Access

In8Bio Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=INAB&period=max&api_key=YOUR_API_KEY